HELIUS MEDICAL TECHNOLOGIES (HSDT)

US42328V8019 - Common Stock

0.507  -0.04 (-7.78%)

After market: 0.5054 0 (-0.32%)

Fundamental Rating

3

HSDT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 189 industry peers in the Health Care Equipment & Supplies industry. While HSDT seems to be doing ok healthwise, there are quite some concerns on its profitability. HSDT is quite expensive at the moment. It does show a decent growth rate.



0

1. Profitability

1.1 Basic Checks

HSDT had negative earnings in the past year.
In the past 5 years HSDT always reported negative net income.
HSDT had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -99.89%, HSDT is not doing good in the industry: 82.35% of the companies in the same industry are doing better.
HSDT has a Return On Equity of -139.39%. This is in the lower half of the industry: HSDT underperforms 74.33% of its industry peers.
Industry RankSector Rank
ROA -99.89%
ROE -139.39%
ROIC N/A
ROA(3y)-108.35%
ROA(5y)-127.05%
ROE(3y)-236.75%
ROE(5y)-248.57%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

HSDT's Gross Margin of 12.79% is on the low side compared to the rest of the industry. HSDT is outperformed by 82.35% of its industry peers.
HSDT's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for HSDT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 12.79%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-38.59%
GM growth 5Y-37.58%

6

2. Health

2.1 Basic Checks

HSDT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for HSDT has been increased compared to 1 year ago.
Compared to 5 years ago, HSDT has more shares outstanding
HSDT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -29.04, we must say that HSDT is in the distress zone and has some risk of bankruptcy.
HSDT's Altman-Z score of -29.04 is on the low side compared to the rest of the industry. HSDT is outperformed by 90.91% of its industry peers.
HSDT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -29.04
ROIC/WACCN/A
WACC8.93%

2.3 Liquidity

HSDT has a Current Ratio of 4.20. This indicates that HSDT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.20, HSDT is in the better half of the industry, outperforming 65.78% of the companies in the same industry.
HSDT has a Quick Ratio of 3.80. This indicates that HSDT is financially healthy and has no problem in meeting its short term obligations.
HSDT has a Quick ratio of 3.80. This is in the better half of the industry: HSDT outperforms 69.52% of its industry peers.
Industry RankSector Rank
Current Ratio 4.2
Quick Ratio 3.8

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 38.97% over the past year.
Looking at the last year, HSDT shows a very negative growth in Revenue. The Revenue has decreased by -18.17% in the last year.
HSDT shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.05% yearly.
EPS 1Y (TTM)38.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.67%
Revenue 1Y (TTM)-18.17%
Revenue growth 3Y-0.81%
Revenue growth 5Y6.05%
Sales Q2Q%-28.91%

3.2 Future

The Earnings Per Share is expected to grow by 29.30% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 142.98% on average over the next years. This is a very strong growth
EPS Next Y60.07%
EPS Next 2Y35.36%
EPS Next 3Y29.3%
EPS Next 5YN/A
Revenue Next Year-2.82%
Revenue Next 2Y31.4%
Revenue Next 3Y199.56%
Revenue Next 5Y142.98%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HSDT. In the last year negative earnings were reported.
Also next year HSDT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

HSDT's earnings are expected to grow with 29.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.36%
EPS Next 3Y29.3%

0

5. Dividend

5.1 Amount

HSDT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

HELIUS MEDICAL TECHNOLOGIES

NASDAQ:HSDT (10/31/2024, 6:30:54 PM)

After market: 0.5054 0 (-0.32%)

0.507

-0.04 (-7.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.62M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -99.89%
ROE -139.39%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 12.79%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 4.2
Quick Ratio 3.8
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)38.97%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y60.07%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-18.17%
Revenue growth 3Y-0.81%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y